Rispenzepine is a chemical compound classified as an atypical antipsychotic, primarily used in the treatment of schizophrenia and related disorders. It functions as a selective antagonist of certain serotonin and dopamine receptors, which contributes to its therapeutic effects. The compound exhibits a unique pharmacological profile, with a preference for serotonin receptor subtypes, which may help mitigate some of the side effects commonly associated with traditional antipsychotics. Rispenzepine is characterized by its moderate lipophilicity, allowing it to cross the blood-brain barrier effectively. Its chemical structure includes a piperazine moiety, which is common among many antipsychotic agents, and it is known for its relatively low incidence of extrapyramidal symptoms compared to older antipsychotics. The compound's safety and efficacy profile continues to be evaluated in clinical settings, and it is important for healthcare providers to monitor patients for potential side effects, including metabolic changes and sedation. Overall, Rispenzepine represents a significant advancement in the pharmacotherapy of psychotic disorders.

Rispenzepine

96449-05-7: Rispenzepine [INN],  11-[(1-methylpiperidin-3-yl)carbonyl]-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-5-one,  (+-)-6,11-Dihydro-11-(1-methylnipecotoyl)-5H-pyrido(2,3-b)(1,5)benzodiazepin-5-one,  UNII-W99LLM73R7,  (- )-6.11-Dihydro-11-(1-methylnipecotoyl)-5H-pyrido(2,3-b)(1,5)benzodiazepin-5-one

Rispenzepine is a peptide that acts as an activator of ion channels. It is used in research as a tool to study the effects of ion channel activation on cells. Rispenzepine is also used to produce antibodies against ion channels, and has been shown to inhibit receptor-ligand interactions.

Rispenzepine, a novel mAChRs M1/M3 antagonist, treats immune, infections, and respiratory issues.

CAS 96449-05-7: Rispenzepine

Rispenzepine

Ref: 3D-WDA44905

Rispenzepine

Ref: TM-T16758